Anti-phospho JAK2 (Tyr972) (rabbit polyclonal)

Species Reactivity	Key Applications	Host	Format	Antibody Type
H, R, Eq, Op, B, Chp, Po	WB	Rb	Affinity Purified	Polyclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

H, R, Eq, Op, B, Chp, Po

Affinity Purified

Polyclonal Antibody

Description
Catalogue Number	09-243
Description	Anti-phospho JAK2 (Tyr972) Antibody
Alternate Names	Janus kinase 2 Janus kinase 2 (a protein tyrosine kinase) tyrosine-protein kinase JAK2
Background Information	JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.

Description

Catalogue Number

09-243

Description

Anti-phospho JAK2 (Tyr972) Antibody

Alternate Names

Janus kinase 2
Janus kinase 2 (a protein tyrosine kinase)
tyrosine-protein kinase JAK2

Background Information

JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.

Product Information
Format	Affinity Purified
Control	Transfected 293T cell lysate treated with SH2B1 beta
Presentation	Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide.

Product Information

Format

Affinity Purified

Control

Transfected 293T cell lysate treated with SH2B1 beta

Presentation

Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide.

Applications
Application	Anti-phospho JAK2 (Tyr972) Antibody detects level of phospho JAK2 (Tyr972) & has been published & validated for use in WB.
Key Applications	Western Blotting
Application Notes	Western Blot Analysis: 2 µg/mL from a previous lot detected phosphorylated JAK2 (Tyr972) in 10 µg of pervanadate-treated L6 cell lysate.

Applications

Application

Anti-phospho JAK2 (Tyr972) Antibody detects level of phospho JAK2 (Tyr972) & has been published & validated for use in WB.

Key Applications

Western Blotting

Application Notes

Western Blot Analysis: 2 µg/mL from a previous lot detected phosphorylated JAK2 (Tyr972) in 10 µg of pervanadate-treated L6 cell lysate.

Biological Information
Immunogen	KLH-conjugated linear peptide corresponding to the protein kinase 2 domain of human JAK2.
Epitope	Protein kinase 2 domain, phosphorylated at Tyr972.
Concentration	Please refer to the Certificate of Analysis for the lot-specific concentration.
Host	Rabbit
Specificity	This antibody recognizes phosphorylated JAK2 at Tyr972.
Species Reactivity	Human Rat Horse Opossum Bovine Chimpanzee Pig
Species Reactivity Note	Demonstrated to react in human and rat. Predicted to react with equine, opossum, bovine, chimpanzee, porcine, platypus, and ape based on 100% sequence homology.
Antibody Type	Polyclonal Antibody
Entrez Gene Number	NP_004963
Entrez Gene Summary	This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq].
Gene Symbol	JAK-2 JTK10
Purification Method	Affinity Purfied
UniProt Number	O60674
UniProt Summary	FUNCTION:Plays a role in leptin signaling and control of body weight by similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction. CATALYTIC ACTIVITY:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. SUBUNIT STRUCTURE: Interacts with SIRPA and SH2B1 by similarity. Interacts with IL23R, SKB1 and STAM2. SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein by similarity. Note: Wholly intracellular, possibly membrane associated by similarity. TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node. DOMAIN: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain by similarity, while the presence of slight differences suggest a different role for domain 1. PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 by similarity. INVOLVEMENT IN DISEASE: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. SEQUENCE SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. Contains 1 FERM domain. Contains 1 protein kinase domain. Contains 1 SH2 domain.
Molecular Weight	~125 kDa observed

Biological Information

Immunogen

KLH-conjugated linear peptide corresponding to the protein kinase 2 domain of human JAK2.

Epitope

Protein kinase 2 domain, phosphorylated at Tyr972.

Concentration

Please refer to the Certificate of Analysis for the lot-specific concentration.

Host

Rabbit

Specificity

This antibody recognizes phosphorylated JAK2 at Tyr972.

Species Reactivity

Human
Rat
Horse
Opossum
Bovine
Chimpanzee
Pig

Species Reactivity Note

Demonstrated to react in human and rat.
Predicted to react with equine, opossum, bovine, chimpanzee, porcine, platypus, and ape based on 100% sequence homology.

Antibody Type

Polyclonal Antibody

Entrez Gene Number

NP_004963

Entrez Gene Summary

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq].

Gene Symbol

JAK-2
JTK10

Purification Method

Affinity Purfied

UniProt Number

O60674

UniProt Summary

FUNCTION:Plays a role in leptin signaling and control of body weight by similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.

CATALYTIC ACTIVITY:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

SUBUNIT STRUCTURE: Interacts with SIRPA and SH2B1 by similarity. Interacts with IL23R, SKB1 and STAM2.

SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein by similarity. Note: Wholly intracellular, possibly membrane associated by similarity.

TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node.

DOMAIN: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain by similarity, while the presence of slight differences suggest a different role for domain 1.

PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 by similarity.

INVOLVEMENT IN DISEASE: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.

Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.

Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.

Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.

SEQUENCE SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.

Contains 1 FERM domain.

Contains 1 protein kinase domain.

Contains 1 SH2 domain.

Molecular Weight

~125 kDa observed

Product Usage Statements
Quality Assurance	Evaluated by Western Blot in transfected 293T cell lysate treated with SH2B1 beta. Western Blot Analysis: 0.1 µg/mL of this antibody detected phosphorylated JAK2 (Tyr972) in 10 µg of 293T cells transfected with WT JAK2 and treated with SH2B1 beta, and less so in 293T cells transfected with mutant JAK2 (phenylalanine) and treated with SH2B1 beta.
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Quality Assurance

Evaluated by Western Blot in transfected 293T cell lysate treated with SH2B1 beta.

Western Blot Analysis: 0.1 µg/mL of this antibody detected phosphorylated JAK2 (Tyr972) in 10 µg of 293T cells transfected with WT JAK2 and treated with SH2B1 beta, and less so in 293T cells transfected with mutant JAK2 (phenylalanine) and treated with SH2B1 beta.

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Stable for 1 year at 2-8°C from date of receipt.

Storage and Shipping Information

Storage Conditions

Stable for 1 year at 2-8°C from date of receipt.

Packaging Information
Material Size	100 µg

Packaging Information

Material Size

100 µg

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Anti-phospho JAK2 (Tyr972) (rabbit polyclonal)

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询